⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20377969 | 1.00 | — | — | |
| SCHEMBL20377961 | 1.00 | — | — | |
| SCHEMBL6295439 | 0.77 | — | — | |
| Hydrochloric Acid SCHEMBL7022020 | 0.76 | ALDH1A1 (0.38) | — | |
| SCHEMBL28911571 | 0.75 | ACHE (0.30) | — | |
| SCHEMBL468462 | 0.74 | CTH (0.34) | — | |
| SCHEMBL18422852 | 0.74 | ALDH1A1 (0.36) | — | |
| SCHEMBL7361490 | 0.73 | — | — | |
| SCHEMBL161143 | 0.72 | — | — | |
| SCHEMBL8768901 | 0.71 | CYP2D6 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 139 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024264025-A2 | THERAPEUTIC TARGETING OF HYPDH/PRODH2 AND PRODH1 TO SUPPRESS 4-HYDROXYPROLINE AND PROLINE CATABOLISM | BUCK INSTITUTE FOR RESEARCH ON AGING (US) | 2024-12-26 | — | — | WO | claimed |
| EP-3328877-B1 | PEPTOID | THE UNIV OF DURHAM (GB) | 2022-08-24 | — | — | EP | claimed |
| US-20180201647-A1 | Peptoid | THE UNIVERSITY OF DURHAM (GB) | 2018-07-19 | — | — | US | claimed |
| WO-2024264025-A2 | THERAPEUTIC TARGETING OF HYPDH/PRODH2 AND PRODH1 TO SUPPRESS 4-HYDROXYPROLINE AND PROLINE CATABOLISM | BUCK INSTITUTE FOR RESEARCH ON AGING (US) | 2024-12-26 | — | — | WO | disclosed |
| EP-3328877-B1 | PEPTOID | THE UNIV OF DURHAM (GB) | 2022-08-24 | — | — | EP | disclosed |
| US-20190292224-A1 | TRIAZOLE-CROSSLINKED AND THIOETHER-CROSSLINKED PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2019-09-26 | — | — | US | disclosed |
| US-20190225650-A1 | PEPTIDOMIMETIC MACROCYCLES AND USE THEREOF IN REGULATING HIF1ALPHA | AILERON THERAPEUTICS, INC. | 2019-07-25 | — | — | US | disclosed |
| US-20190185518-A9 | WARHEAD-CONTAINING PEPTIDOMIMETIC MACROCYCLES AS MODULATORS OF BFL-1 | AILERON THERAPEUTICS, INC. | 2019-06-20 | — | — | US | disclosed |
| US-10308699-B2 | Peptidomimetic macrocycles | AILERON THERAPEUTICS, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-10300109-B2 | Peptidomimetic macrocycles | AILERON THERAPEUTICS, INC. (US) | 2019-05-28 | — | — | US | disclosed |
| US-10246491-B2 | Peptidomimetic macrocycles and use thereof in regulating HIF1alpha | AILERON THERAPEUTICS, INC. (US) | 2019-04-02 | — | — | US | disclosed |
| US-20090326192-A1 | BIOLOGICALLY ACTIVE PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2009-12-31 | — | — | US | disclosed |
| EP-2114428-A2 | TRIAZOLE MACROCYCLE SYSTEMS | Aileron Therapeutics, Inc. (US) | 2009-11-11 | — | — | EP | disclosed |
| US-20090275519-A1 | Therapeutic peptidomimetic macrocycles | AILERON THERAPEUTICS, INC. (US) | 2009-11-05 | — | — | US | disclosed |
| WO-2009126292-A2 | BIOLOGICALLY ACTIVE PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2009-10-15 | — | — | WO | disclosed |
| WO-2009099677-A2 | THERAPEUTIC PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2009-08-13 | — | — | WO | disclosed |
| US-20080262200-A1 | Triazole Macrocycle Systems | AILERON THERAPEUTICS, INC., A DELAWARE CORPORATION (US) | 2008-10-23 | — | — | US | disclosed |
| WO-2008104000-A2 | TRIAZOLE MACROCYCLE SYSTEMS | AILERON THERAPEUTICS, INC. (US) | 2008-08-28 | — | — | WO | disclosed |
| EP-0792146-A1 | INACTIVATION OF PATHOGENS USING HYDROXYMETHYLAMINES | HEMASURE, INC. (US) | 1997-09-03 | — | — | EP | disclosed |
| WO-1997002028-A1 | INACTIVATION OF PATHOGENS USING HYDROXYMETHYLAMINES | HEMASURE, INC. (US) | 1997-01-23 | — | — | WO | disclosed |